Efficacy and Safety of Docetaxel followed by QL1706 as Second-Line Treatment for Advanced Driver Gene-Negative Non-Small Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: bb3eb86674c6cd0ec06ead91a5baadb18b3a7144
First added on: Oct 10, 2026